2023 Department of Pediatrics Academic Annual Report

GRANTS AWARDED IN 2023 (continued)

INVESTIGATOR PROJECT TITLE

SPONSOR

DIRECT AWARDED

Pinninti, Swetha Geetha

A Phase 2/3, Interventional Safety, Pharmacokinetics, and Efficacy, Open Label, Multi-Center, Single-Arm Study to Investigate Orally Administered PF 07321332 (NIRMATRELVIR)/RITONAVIR in NonHospitalized Symptomatic Pediatric Participants with COVID-19 who are at Risk of Progression to Severe Disease

Pfizer Inc., U.S. Pharmaceuticals Group

$193,842

Hutto, Susan C.

Pediatric HIV/AIDS Cohort Study (PHACS): 2020, SMARTT

Harvard College

$175,995

Boppana, Suresh B.

A Phase 3, Randomized, Placebo Controlled, Observer-Blinded Trial to Evaluate the Safety of A 6-Valent OspA Based Lyme Disease Vaccine (VLA15) in Healthy Children 5 Through 17 Years of Age A Phase 1, Open-Label, Age-Descending, Dose-Finding Study, and A Phase 2/3 Placebo-Controlled, Randomized, Double-Blinded Study to Evaluate the Safety, Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine (RSVpreF) in Children 2 to <18 years of age at High Risk of RSV Disease

Pfizer Inc., U.S. Pharmaceuticals Group

$110,874

Boppana, Suresh B.

Pfizer Inc., U.S. Pharmaceuticals Group

$89,223

Sanchez, Veronica

HCMV UL71 Functional Interactions and Trafficking

Kaul Pediatric Research Institute of the Alabama Children’s Hospital Foundation

$70,000

Pinninti, Swetha Geetha

A Phase 2, Two-Part Study (Open-Label [Part 1] Followed by Observer-Blind/Randomized [Part 2]) to Evaluate the Safety, Tolerability, Reactogenicity and Effectiveness of mRNA 1273.214 SARS-CoV-2 Vaccine in Participants Aged 12 Weeks to < 6 Months

ModernaTX, Inc.

$54,784

Kimberlin, David Winston

A Phase 2 Randomized, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

Leidos, Inc.

$53,589

Britt, William J.

Tegument Envelope Protein Interactions in CMV Envelopment

NIH

$291,594

Poole, Claudette

Rural Health Care Coordination Network Program

HRSA

$238,092

2023 Academic Annual Report

96